Group 1: Industry Insights - The insurance industry is experiencing improvements on both the liability and asset sides, with significant upward valuation potential [1] - The China Insurance Industry Association held a seminar focusing on the high-quality development of commercial health insurance, highlighting a compound annual growth rate of over 20% in commercial health insurance over the past decade [1] - The association estimates that by 2025, the total compensation amount for innovative drugs and medical devices in commercial health insurance will reach approximately 14.7 billion, with a compound annual growth rate of 70% [1] Group 2: Policy Developments - The Shanghai Financial Regulatory Bureau released a development action plan for high-quality pension finance in the banking and insurance sectors, proposing 20 measures to enhance the pension security system [2] - The plan encourages insurance institutions to participate in the comprehensive management of basic pension insurance funds and to innovate commercial pension insurance products [2] Group 3: Company Initiatives - Major insurance companies, including China Life and PICC, have established specialized health management subsidiaries to create a comprehensive health and wellness service ecosystem [3] - The industry is expected to accelerate its layout in the health and wellness sector, leveraging policy guidance to develop a "insurance products + health services" model for growth [3]

展望后市，黄金长期上涨趋势获机构普遍看好。高盛在最新报告中，将黄金今年底目标价从每盎司4900美元上调至5400美元，理由是私人部门投资者和中央 银行对黄金的需求不断增长。高盛分析师预计，各国央行今年每月将购买60吨黄金，同时随着美联储降息，黄金ETF的持有量也将增加。各国央行已开始通 过传统的ETF，与私人部门投资者争夺有限的黄金。 （来源：财闻） 高盛在最新报告中，将黄金今年底目标价从每盎司4900美元上调至5400美元，理由是私人部门投资者和中央银行对黄金的需求不断增长。 1月26日，截至发稿，现货黄金首次突破5000美元/盎司，日内涨超1%。现货白银盘初再创新高，现报105.05美元/盎司，涨幅超2%。 | | | 东吴证券表示，2026年，在市场波动可能延续、全球央行持续购金去美元化的背景下，黄金作为具备长期保值功能和低相关性的资产，在资产配置中，更值 得稳健型投资者关注。 ...

Group 1 - Core viewpoint: Elon Musk announced at the World Economic Forum that Tesla and SpaceX will build 100GW capacity for ground and space photovoltaics, respectively, expected to be completed by the end of 2028 [1] - The demand for space photovoltaics is expected to surge due to the exponential growth in satellite launches, with SpaceX accelerating the construction of its Starlink system [2] - Silicon-based HJT technology is identified as the optimal short-term solution for space photovoltaics due to its lightweight, cost-effectiveness, and lack of raw material constraints [2] Group 2 - The overseas ground photovoltaic market is also experiencing strong demand, with the US solar market projected to grow at a compound annual growth rate of over 20% from 2024 to 2029 [3] - China is expected to dominate the global market in 2024, with over 80% of the production capacity in silicon materials, wafers, cells, and modules [3] - Key equipment manufacturers such as Jing Sheng, Maiwei, and Aotwei are positioned to benefit from this growth, with significant market shares in their respective segments [3]

Core Viewpoint - Dongwu Securities report indicates that Fuan Energy's diversified business development has exceeded expectations, ensuring shareholder returns [1] Financial Performance - The company is projected to achieve a net profit attributable to shareholders of 1.001 billion yuan in 2025, representing a year-on-year growth of 17.3% [1] - In Q4 2025, the net profit attributable to shareholders is expected to reach 510 million yuan, showing a year-on-year increase of 30.6%, surpassing previous expectations [1] - The profit forecasts for 2025-2027 have been revised upwards to 1.001 billion, 1.070 billion, and 1.117 billion yuan respectively, from the original estimates of 872 million, 922 million, and 976 million yuan [1] Dividend Policy - The company plans to maintain a dividend payout ratio of no less than 65% for the years 2025-2027, ensuring returns for shareholders [1] Business Strategy - The company adheres to an "Energy + Technology + Supply Chain" strategy, focusing on urban natural gas operations while actively advancing in petrochemical products, hydrogen energy, thermal energy, photovoltaics, and energy storage [1] - Continuous efforts are being made in technology research and development, equipment manufacturing, supply chain operations, and other extended businesses [1] Market Outlook - The natural gas business is expected to develop steadily, while new energy, supply chain, extended, and technology R&D and manufacturing businesses are flourishing [1] - The rating for the company is maintained at "Buy" [1]

Core Viewpoint - The company, Jiechang Drive, has exceeded market expectations in its 2025 performance forecast, with a focus on deepening its layout in the robotics components sector [1] Group 1: Company Performance - Jiechang Drive is a leader in the linear drive industry, with subsidiaries in multiple global locations and five major production bases in Ningbo, Xinchang, Malaysia, the United States, and Europe [1] - The first phase of the European logistics and production base has been completed, enhancing collaboration with its German subsidiary and Austrian LOGICDATA, which will improve technology research and development, production delivery, and supply chain management capabilities in Europe [1] - The company has established an efficient customer demand response mechanism, effectively increasing customer satisfaction and loyalty, leading to a rise in market share and steady growth in linear drive control business [1] Group 2: Future Outlook - For 2026, the company expects its linear drive business revenue to maintain a steady year-on-year growth of 20-30% [1] - The company is developing its own robotics components product line, creating a second growth curve [1] - Due to the ongoing deepening of its overseas layout and stable performance growth, the company has revised its net profit forecasts for 2025-2027 to 416 million, 545 million, and 712 million yuan respectively, representing year-on-year increases of 47%, 31%, and 31% [1] - The current price corresponds to a PE ratio of 36x, 27x, and 21x for the years 2025, 2026, and 2027, respectively, maintaining a "buy" rating [1]

东吴证券发布研报称，维持康宁杰瑞制药-B(09966)"买入"评级，考虑到2025年公司有多款ADC新管线 完成临床前研发，该行提高了对研发费用的预测水平，相应影响归母净利润水平，2025-2026年归母净 利润分别下调为-1.15/-0.97亿元，原值为0.14/0.63亿元，新增2027年归母净利润预测为-0.26亿元。随着 公司后续产品KN026有望国内上市，JSKN003也即将申报上市，该行预计未来公司亏损将逐步缩小。同 时基于公司后备管线的逐步进入临床阶段，公司研发能力进入良性发展循环。 自研平台持续发力，多款新ADC分子即将进入临床 公司自研的技术平台持续产出新管线，在PD-L1靶点管线中，PD-L1/ITGB6/8多功能ADCJSKN022展现 出优于单抗ADC的内吞效率和体内外杀伤活性，该管线目前已经在2025年10月启动了I期临床。PD- L1/VEGFR2双抗ADCJSKN027整合了细胞毒杀伤、抗血管及免疫调节三重机制，公司在2025年12月已 经向中国药监局提交IND申请并获得受理，2026年有望开展针对JSKN027的I期临床研究。后续还有 EGFR/HER3双抗双载荷ADCJSKN ...

Core Viewpoint - Dongwu Securities maintains a "Buy" rating for Kangning Jereh Pharmaceutical-B (09966), anticipating multiple ADC pipelines to complete preclinical development by 2025, leading to adjustments in R&D expense forecasts and net profit estimates for 2025-2027 [1] Group 1: Financial Projections - The forecast for net profit attributable to the parent company is adjusted to -115 million yuan for 2025 and -97 million yuan for 2026, down from 14 million yuan and 63 million yuan respectively; a new forecast for 2027 is set at -26 million yuan [1] - The company is expected to gradually reduce losses as products like KN026 are anticipated to be launched domestically, with JSKN003 also nearing its application for market approval [1] Group 2: Product Pipeline Developments - KN026, a HER2 bispecific monoclonal antibody, has had its application for marketing approval accepted by NMPA, with expectations for approval by the end of 2026 or in 2027; the domestic rights have been granted to CSPC Pharmaceutical Group, while the company retains exclusive production rights [1] - JSKN003, the company's first ADC pipeline, is expected to submit a domestic application for HER2-positive breast cancer in 2026, with promising efficacy data presented at the 2025 ESMO conference for ovarian and colorectal cancers [2] Group 3: Research and Development Advancements - The company's self-developed platform continues to yield new pipelines, with the PD-L1/ITGB6/8 multifunctional ADC JSKN022 showing superior internalization efficiency and cytotoxic activity, having initiated Phase I clinical trials in October 2025 [3] - The PD-L1/VEGFR2 bispecific ADC JSKN027 has integrated multiple mechanisms and has received acceptance for its IND application, with Phase I clinical trials expected to commence in 2026 [3] - Additional ADCs, such as EGFR/HER3 bispecific dual-load ADC JSKN021, are anticipated to enter clinical development stages [3]

1月22日，AI语音厂商思必驰科技股份有限公司在江苏证监局办理辅导备案登记，拟首次公开发行股票 并上市，辅导券商为东吴证券。 ...

Core Viewpoint - Dongwu Securities aims to achieve high-quality development by integrating into national and regional strategies, focusing on serving small and medium-sized enterprises (SMEs) while leveraging its strengths in the Yangtze River Delta region [1][2]. Company Development - Established in 1993, Dongwu Securities has evolved from a regional broker to a comprehensive securities firm with 30 branches and 130 business units nationwide, positioning itself strategically in Suzhou and the Yangtze River Delta [2]. - As of Q3 2025, the company's total assets reached 217 billion yuan, and net assets reached 42.8 billion yuan, doubling and increasing by 1.5 times respectively compared to the end of the 13th Five-Year Plan [2]. - The company has seen significant growth, with total assets increasing by 7,000 times, net assets by 3,500 times, revenue by 420 times, and net profit by 260 times since its inception [2]. Strategic Focus - Dongwu Securities emphasizes a differentiated development path rather than blindly pursuing scale, focusing on its core strengths and integrating into the local economy [3][4]. - The company has identified five strategic guidelines for development: focusing on its base, integrating into the Yangtze River Delta, serving SMEs, enhancing compliance and risk control, and promoting corporate governance and social responsibility [4]. Industry Context - The 14th Five-Year Plan highlights the importance of building a financial powerhouse, urging financial institutions to focus on their core businesses and develop unique strengths [5]. - Dongwu Securities recognizes the need for three fundamental shifts in the industry: from scale expansion to functional priority, from homogeneous competition to distinctive advantages, and from passive compliance to proactive risk control [5]. Service Orientation - The company aims to serve the real economy by efficiently allocating financial resources to support national strategies and regional development [6][7]. - Dongwu Securities positions itself as a financial advisor for local economies, providing comprehensive financial solutions to key industries in Suzhou and the Yangtze River Delta [6][7]. Innovation and Technology - The company is committed to enhancing its professional capabilities through innovation, focusing on the growth patterns of SMEs and providing comprehensive listing guidance services [8][9]. - Dongwu Securities is advancing its digital transformation, utilizing AI technologies to improve customer service and operational efficiency [9][10]. Risk Management - The company prioritizes compliance and risk management, establishing a comprehensive risk management system supported by AI technology for dynamic oversight [11]. - Dongwu Securities promotes a culture of compliance throughout the organization, ensuring that all employees are aware of and adhere to compliance standards [11]. Future Vision - Dongwu Securities is determined to pursue a differentiated development path, aiming to become a first-class modern investment bank while contributing to the modernization of China's economy [12].

Core Viewpoint - Dongwu Securities aims to achieve high-quality development by integrating into regional strategies and serving small and medium-sized enterprises (SMEs) as a modern investment bank [1][2]. Group 1: Company Strategy and Development - Dongwu Securities has established a strategic direction of "based on the local area, integrating into the Yangtze River Delta, and serving SMEs" [1][2]. - The company has evolved from a regional broker to a comprehensive broker with a national presence, operating 30 branches and 130 business units [2]. - As of Q3 2025, Dongwu Securities' total assets reached 217 billion yuan, and net assets reached 42.8 billion yuan, doubling and increasing by 1.5 times compared to the end of the 13th Five-Year Plan [2]. Group 2: Competitive Advantages and Market Position - Dongwu Securities has seen significant growth, with total assets increasing by 7,000 times and net assets by 3,500 times since its inception [3]. - The company focuses on a differentiated development path rather than blindly pursuing scale, leveraging the economic vitality of Suzhou as its core base [3][4]. - The firm has developed a unique identity by serving innovative SMEs, which distinguishes it from competitors [4]. Group 3: Operational Strategies and Innovations - Dongwu Securities has outlined five strategic guidelines for development, including enhancing compliance and risk control, strengthening capital, and optimizing talent [4]. - The company emphasizes the importance of integrating financial services with local industrial planning, particularly in sectors like biomedicine and high-end manufacturing [9]. - Dongwu Securities is committed to digital transformation, utilizing AI to enhance customer service and operational efficiency [8]. Group 4: Risk Management and Compliance - The company prioritizes a comprehensive risk management system, combining institutional frameworks with technological empowerment [10]. - Dongwu Securities promotes a culture of compliance throughout the organization, ensuring that compliance awareness is ingrained in every employee [10]. - The firm has established a responsibility system for risk control, ensuring accountability at all levels of operation [10].